5G-EMERALD: Amivantamab in Malignant Brain Tumours
Abroad (travel likely)RecruitingPHASE1
Conditions
Malignant Primary Gliomas · Glioblastoma Multiform (Grade IV Astrocytoma) · Diffuse Hemispheric Glioma, H3 G34-Mutant · Glioblastoma Multiforme (GBM)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Cambridge University Hospitals, Cambridge, United Kingdom
The Royal Marsden Hospital - Drug Development Unit, Sutton, United Kingdom
Study leads
Juanita Lopez, MD, PhD
Study Director
National Health Service, UK